ORIC · ORIC Pharmaceuticals Inc
United States · RS rating 27 · As of 2026-11-03
| Price | 9.59 USD |
|---|---|
| 1-day change | +5.7% |
| RS rating (overall / 1M / 3M / 12M) | 27 / 18 / 25 / 33 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 30 / 25 / 30 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +9.1% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +34.5% |
| Market cap (USD) | $1.2B |